Edgen Stock·Sep 25 2025, 04:03戻る
戻る
Prime Medicine Shares Advance on Pipeline Updates and Strategic Adjustments
Edgen Stock·Sep 25 2025, 04:03
[1] Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME) | Seeking Alpha[2] Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now[3] Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP